Kimia Biosciences (BOM:530313) Debt-to-Revenue : 0.00 (As of . 20)

View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Kimia Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₹0.00 Mil. Kimia Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₹0.00 Mil. Kimia Biosciences's annualized Revenue for the quarter that ended in . 20 was ₹0.00 Mil.

Kimia Biosciences Debt-to-Revenue Historical Data

The historical data trend for Kimia Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kimia Biosciences Debt-to-Revenue Chart

Kimia Biosciences Annual Data

Trend

Debt-to-Revenue

Kimia Biosciences Semi-Annual Data

Debt-to-Revenue

Competitive Comparison of Kimia Biosciences's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Kimia Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kimia Biosciences's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kimia Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kimia Biosciences's Debt-to-Revenue falls into.

Kimia Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Kimia Biosciences's Debt-to-Revenue for the fiscal year that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	N/A
	=	N/A

Kimia Biosciences's annualized Debt-to-Revenue for the quarter that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (. 20) Revenue data.

Kimia Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kimia Biosciences (BOM:530313) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » Debt-to-Revenue

Traded in Other Exchanges

N/A

Address

Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034

Website

https://www.kimiabiosciences.com

Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences (BOM:530313) Headlines

No Headlines